During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|October 9, 2012
FDA approves cysteamine ophthalmic solution 0.44% for treatment of corneal cystine crystals in cystinosis patients
FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44%, a topical ophthalmic therapeutic, developed in partnership with the National Institutes of Health (NIH), for the treatment of corneal cystine crystal accumulation in patients with cystinosis.
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
2
Kaiser’s formulary chief makes his case for a ‘total value’ model on biologics | HSES 2026
3
More pluses for GLP-1s for obstructive sleep apnea | CHEST 2026
4
Is there a dangerous 'weekend effect' to hospitals admissions? The verdict is split | CHEST 2026
5